Stockholm Stock Exchange

Covid-19 Damaging Financial Wellbeing, Finds Credit Management Group Intrum

Retrieved on: 
Tuesday, June 9, 2020

The whitepaper, published by credit management group Intrum, outlines the financial impact of Covid-19 on private households across 24 European countries.

Key Points: 
  • The whitepaper, published by credit management group Intrum, outlines the financial impact of Covid-19 on private households across 24 European countries.
  • Across Europe, millennials are more likely to say their financial wellbeing has suffered, than other age groups.
  • Intrum is the industry-leading provider of Credit Management Services with a presence in 24 markets in Europe.
  • Intrum is headquartered in Stockholm, Sweden and the Intrum share is listed on the Nasdaq Stockholm exchange.

Calliditas Therapeutics Prices its Initial Public Offering on The Nasdaq Global Select Market in the United States

Retrieved on: 
Friday, June 5, 2020

Trading of the ADSs on The Nasdaq Global Select Market commences on June 5, 2020, under the symbol "CALT".

Key Points: 
  • Trading of the ADSs on The Nasdaq Global Select Market commences on June 5, 2020, under the symbol "CALT".
  • If the Over-Allotment Option is exercised in full, the Global Offering will consist of 4,845,692 ADSs and 924,000 common shares.
  • Trading of the ADSs on The Nasdaq Global Select Market commences on June 5, 2020, under the symbol "CALT".
  • Calliditas is listed on Nasdaq Stockholm (ticker: CALTX) and The Nasdaq Global Select Market (ticker: CALT).

Calliditas Therapeutics Prices its Initial Public Offering on The Nasdaq Global Select Market in the United States

Retrieved on: 
Friday, June 5, 2020

Trading of the ADSs on The Nasdaq Global Select Market commences on June 5, 2020, under the symbol "CALT".

Key Points: 
  • Trading of the ADSs on The Nasdaq Global Select Market commences on June 5, 2020, under the symbol "CALT".
  • If the Over-Allotment Option is exercised in full, the Global Offering will consist of 4,845,692 ADSs and 924,000 common shares.
  • Trading of the ADSs on The Nasdaq Global Select Market commences on June 5, 2020, under the symbol "CALT".
  • Calliditas is listed on Nasdaq Stockholm (ticker: CALTX) and The Nasdaq Global Select Market (ticker: CALT).

Nasdaq Launches Service to Track Environmental, Social, and Governance Impact

Retrieved on: 
Thursday, May 14, 2020

STOCKHOLM, Sweden, May 14, 2020 (GLOBE NEWSWIRE) -- Nasdaq (Nasdaq: NDAQ) today announced the launch of a new service, the Nasdaq ESG Footprint , to provide banks and institutional investors the ability to help their clients track the Environmental, Social, and Governance (ESG) impact of their portfolios and individual securities based on variety of parameters.

Key Points: 
  • STOCKHOLM, Sweden, May 14, 2020 (GLOBE NEWSWIRE) -- Nasdaq (Nasdaq: NDAQ) today announced the launch of a new service, the Nasdaq ESG Footprint , to provide banks and institutional investors the ability to help their clients track the Environmental, Social, and Governance (ESG) impact of their portfolios and individual securities based on variety of parameters.
  • The Nordea share is listed on the Nasdaq Helsinki, Nasdaq Copenhagen and Nasdaq Stockholm exchanges.
  • Nasdaq (Nasdaq: NDAQ) is a global technology company serving the capital markets and other industries.
  • To learn more about the company, technology solutions and career opportunities, visit us on LinkedIn, on Twitter @Nasdaq, or at www.nasdaq.com .

Invitation to Teleconference/Audio Transmission

Retrieved on: 
Thursday, April 23, 2020

To access the audio transmission, please click on the link below: https://tv.streamfabriken.com/concordia-maritime-q1-2020

Key Points: 
  • To access the audio transmission, please click on the link below: https://tv.streamfabriken.com/concordia-maritime-q1-2020
    Questions can be posed verbally via the teleconference, or in writing via the audio transmission.
  • Participants will subsequently also have the opportunity to review the Interim Report for Q1 2020 as a recorded version on Concordia Maritime's website, under Investor Relations.
  • Our focus is on the cost-effective and secure transportation of refined petroleum products and vegetable oils.
  • Concordia Maritime's Series B share has been listed on Nasdaq OMX Stockholm since 1984. www.concordiamaritime.com

Invitation to Teleconference/Audio Transmission

Retrieved on: 
Thursday, April 23, 2020

To access the audio transmission, please click on the link below: https://tv.streamfabriken.com/concordia-maritime-q1-2020

Key Points: 
  • To access the audio transmission, please click on the link below: https://tv.streamfabriken.com/concordia-maritime-q1-2020
    Questions can be posed verbally via the teleconference, or in writing via the audio transmission.
  • Participants will subsequently also have the opportunity to review the Interim Report for Q1 2020 as a recorded version on Concordia Maritime's website, under Investor Relations.
  • Our focus is on the cost-effective and secure transportation of refined petroleum products and vegetable oils.
  • Concordia Maritime's Series B share has been listed on Nasdaq OMX Stockholm since 1984. www.concordiamaritime.com

Interim Report January-March 2020: Mycronic AB

Retrieved on: 
Thursday, April 23, 2020

In a time marked by uncertainty and turbulence, I feel confident in Mycronic's solid financial position and healthy liquidity.

Key Points: 
  • In a time marked by uncertainty and turbulence, I feel confident in Mycronic's solid financial position and healthy liquidity.
  • In recent years, we have strengthened our aftermarket sales, which accounted for 28 percent of the Group's sales in 2019.
  • Mycronic AB (publ) is listed on NASDAQ Stockholm, Large Cap.
  • The information in this report is published in accordance with the EU Market Abuse Regulation and the Swedish Securities Act.

Interim Report January-March 2020: Mycronic AB

Retrieved on: 
Thursday, April 23, 2020

In a time marked by uncertainty and turbulence, I feel confident in Mycronic's solid financial position and healthy liquidity.

Key Points: 
  • In a time marked by uncertainty and turbulence, I feel confident in Mycronic's solid financial position and healthy liquidity.
  • In recent years, we have strengthened our aftermarket sales, which accounted for 28 percent of the Group's sales in 2019.
  • Mycronic AB (publ) is listed on NASDAQ Stockholm, Large Cap.
  • The information in this report is published in accordance with the EU Market Abuse Regulation and the Swedish Securities Act.

Oncopeptides Strengthens its Organization by Appointing Karolina Vilval as General Counsel

Retrieved on: 
Monday, March 2, 2020

STOCKHOLM, March 2, 2020 /PRNewswire/ -- Oncopeptides AB (Nasdaq Stockholm: ONCO) announced today that Karolina Vilval has been appointed as General Counsel of Oncopeptides.

Key Points: 
  • STOCKHOLM, March 2, 2020 /PRNewswire/ -- Oncopeptides AB (Nasdaq Stockholm: ONCO) announced today that Karolina Vilval has been appointed as General Counsel of Oncopeptides.
  • Karolina has 15 years of experience from different positions at Swedish Orphan Biovitrum.
  • Prior to joining Oncopeptides, she served as Associate Legal Director at Gilead Sciences Sweden AB for business area Oncology, HIV and Inflammation.
  • Oncopeptides' headquarters is in Stockholm, Sweden, and the company is listed in the Mid Cap segment on Nasdaq Stockholm with the ticker ONCO.

Oncopeptides Strengthens its Organization by Appointing Karolina Vilval as General Counsel

Retrieved on: 
Monday, March 2, 2020

STOCKHOLM, March 2, 2020 /PRNewswire/ -- Oncopeptides AB (Nasdaq Stockholm: ONCO) announced today that Karolina Vilval has been appointed as General Counsel of Oncopeptides.

Key Points: 
  • STOCKHOLM, March 2, 2020 /PRNewswire/ -- Oncopeptides AB (Nasdaq Stockholm: ONCO) announced today that Karolina Vilval has been appointed as General Counsel of Oncopeptides.
  • Karolina has 15 years of experience from different positions at Swedish Orphan Biovitrum.
  • Prior to joining Oncopeptides, she served as Associate Legal Director at Gilead Sciences Sweden AB for business area Oncology, HIV and Inflammation.
  • Oncopeptides' headquarters is in Stockholm, Sweden, and the company is listed in the Mid Cap segment on Nasdaq Stockholm with the ticker ONCO.